Monthly Meeting
Local Seminars
The Nucleus
Contact Us



Other Events

NESACS 2019 Election Results
Raj (SB) Rajur (w)
Michael Singer (w)
Dorothy Phillips (w)
Richards Medal Committee: (2)
Mary Jane Shultz (w)
Mingdi Yan (w)
Esselen Award Committee: (2)
Karen Allen (w)
Katherine Mirica (w)
Councilor/Alternate Councilor:
Lisa Marcaurelle (c)
Mary Jane Shultz (c)
Malika Jeffries-EL (c)
Tom Gilbert (c)
Sofia Santos (c)
Sonja Strah-Pleynet (c)
Mary Mahaney (a)
Jens Breffke (a)
Kap-Sun Yeung (a)
Michael Singer (a)
Hicham Fenniri (a)
Ashis Saha (a)
Director-at-Large: (2)
David Harris (w)
Mark Tebbe (w)
142 Michael Filosa

Targeted Protein Degradation: From Chemical Biology to Drug Discovery
Presented by:
Biochemical Pharmacology Discussion Group
The New York Academy of Sciences
Tuesday, September 24, 2019, 8:30 AM - 6:00 PM
New York Academy of Sciences
7 World Trade Center, 250 Greenwich St, 40th Fl, New York, NY

FEATURED SPEAKERS: James Bradner, MD, Novartis Institutes for BioMedical Research
DESCRIPTION: Targeted protein degradation is a new therapeutic approach with potential to inhibit “undruggable” drivers of disease. This symposium will highlight the latest advances in the field of targeted protein degradation and showcase its benefits over traditional small molecule inhibitors.
ABSTRACT DEADLINEAugust 2, 2019 Early Bird Discount ends 8/16/19
More information ...

Proposals due by August 12th:


Preliminary announcement!
The 23rd Annual Andrew H. Weinberg Memorial Lecture
More details will be in the October issue of The Nucleus and on this web page in October.
Terry J. Fry, MD,
Children’s Hospital Colorado, Co-Director of the Human Immunology
and Immunotherapy Initiative
Thursday, October 24, 2019
4:00 pm – 5:00 pm.
Yawkey Conference Center, 3rd Floor, Y306 and Y307,
Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215
Dr. Fry was among the first scientists to investigate the potential to insert modified genes into a child’s own
T-cells to target CD19, a surface protein found on nearly all cells affected by acute lymphoblastic leukemia
(ALL). The first product using this technology was approved by the FDA for pediatric use in August 2017,
achieved an astonishing 80% remission rate in children with leukemia previously resistant to all other
therapies including conventional bone marrow transplant.

Nada Jabado Presents the 22nd Annual
Andrew H. Weinberg Memorial Lecture
By Robert Levy, Dana-Farber Cancer Institute
Dubbing it the “Peter Pan effect,” the presenter of the 22nd annual Andrew H. Weinberg Memorial Lecture described how genetic mutations can stall the development of certain brain cells and leave them in a state of perpetual immaturity. The result can be high grade glioma (HGG), one of the most lethal and disabling forms of brain cancer in children and young adults.
At the Sept. 6, 2018 event in the Yawkey Center, Nada Jabado, MD, PhD, of McGill University discussed her research into the fundamental causes of HGG, which led to the discovery that at the molecular level HGG is strikingly different in adults and children. She focused on research showing the disease is rooted in “epigenetic” abnormalities that occur during the process of brain development.
Mutations in certain key genes create abnormalities in proteins known as histones, which provide the spool around which DNA is wrapped within cells. Histones disfigured by such mutations are known as “oncohistones.” In the developing brain, oncohistones can disrupt the activity of genes needed for cells to mature, leading to HGG and other types of tumors.
These discoveries underscore the need for pediatric oncologists specializing in HGG to “be bold” in developing new therapies, Jabado said – potentially by combining different therapies capable of counteracting the abnormalities in oncohistones.
The Andrew H. Weinberg Memorial Endowment Fund was created with the support of family and friends of Dana-Farber patient Andrew H. Weinberg, along with the Medicinal Chemistry Group of the Northeastern section of the American Chemical Society and Dana-Farber. The fund is dedicated to bringing researchers from the field of cancer drug development together with those in the biomedical research and clinical care communities at large, helping to foster an environment for synergy and originality in cancer research, with a particular focus on pediatric oncology.
Comments by the Committee Chair:
“Dr. Jabado delivered an inspiring lecture detailing the molecular underpinnings of some of the most aggressive cancers we see in children. By unraveling the causes of these highgrade gliomas, her work is pointing us to potential new epigenetic therapies to be considered in future clinical trials.”
Steven DuBois, MD MS, Chair, Weinberg Symposium Committee
To learn more, please see some of Dr. Jabado’s recent high-impact publications:

Please note past lectures have been reformatted and can be viewed at new websites see below:
The 18th Annual Andrew H. Weinberg Annual Memorial Lecture June 19, 2014
Luis Alberto Diaz, Jr., M.D Associate Professor, Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and the Ludwig Center for Cancer Genetics and Therapeutics, Novel clinical applications of cancer genomics
The 19th Annual Andrew H. Weinberg Annual Memorial Lecture October 29, 2015
Gregory Reaman, M.D., Associate Director of Oncology Sciences Office of Hematology and Oncology Products Center for Drug Evaluation and Research, U.S. Food and Drug Administration, and Professor of Pediatrics George Washington University School of Medicine and Health Sciences, “Drug Development for Pediatric Cancers – Turning Challenges into Opportunities: A View from the Other Side”
The 20th Annual Andrew H. Weinberg Annual Memorial Lecture September 28, 2016
Mignon Lee-Cheun Loh, MD. The Benioff Professor of Clinical Pediatrics and Chief of Pediatric Hematology/Oncology, The University of California, San Francisco Benioff Children’s Hospital, “New Genomic and Immunotherapeutic Approaches to Childhood, Adolescent, and Young Adult ALL—What’s Next”
The 21th Annual Andrew H. Weinberg Annual Memorial Lecture November 1, 2017
James E. Bradner, M.D., President of the Novartis Institutes for BioMedical Research, "New Paths to the Waterfall: Rethinking the Science of Therapeutics for Pediatric Malignancies"
The 22nd Annual Andrew H. Weinberg Annual Memorial Lecture September 6, 2018
Nada Jabado, M.D., Ph.D.Professor of Pediatrics and Human Genetics, McGill University,The Research Institute of the McGill University Health Center, “Oncohistones: Exquisite Opportunities and Therapeutic Vulnerabilities”

Science and Beer combine at
the Pint of Science Festival
By Christine Caputo
Before the 20th century, new scientific discoveries were often discussed and presented to the public in pubs and coffee shops.* This practice has diminished over time, but a new science festival has revived this concept. Pint of Science was started by research scientists at Imperial College, London, UK in 2012. During the first Pint of Science Festival, there were events held in 3 UK cities. The concept is to bring local researchers to pubs to communicate their cutting-edge scientific research to the public in a relaxed and accessible atmosphere. No prior scientific expertise is required. Since 2013, the popularity of Pint of Science has grown exponentially, bringing events to 300 cities in 21 countries worldwide. It is currently the largest science festival held globally but has thus far gained little foothold in the US.
Three nights of talks were held in the New Hampshire and Maine seacoast during the Pint of Science Festival, which
is the main event that takes place annually in mid-May. Themes this year included “From Atoms to Galaxies (and
everything in between)”, “Planet Earth”, and “Our Bodies:
Infectious Diseases” featuring speakers from The University
of New Hampshire, Chemistry, Physics, Molecular and Cellular Biology, Space Science, Ocean, Civil and Chemical Engineering departments. Approximately 180 people attended the events here in NH this year; all three nights of the festival were sold out! Other Pint events were held in nine cities across the US and the event is gradually gaining steam, but it relies on grassroots organization by local scientists.
We are grateful for financial support from the Northeastern
Section of the American Chemical Society (NESACS) and
the University of New Hampshire, Department of Chemistry.
We also had two brewery hosts, Garrison City Beerworks in
Dover, NH, and Tributary Brewery in Kittery, ME, who were
thrilled to partner with us and host the events. Several graduate students volunteered their time to run the events, distribute flyers, act as online social media influencers and sell tickets. Interest in the festival coincides with a surge in interest in local brewpubs. That means that there are many possible venues across the Northeast that would be great locations for Pint of Science events. Pint also provides a wonderful opportunity for students to engage in science communication with the public, which is essential as they become highly qualified scientists in the workforce and in our communities.
If you are interested in hosting a Pint of Science event in
your community, please email us For more information about Pint, please check out the website We hope to see you at #Pint20!

BAGIM Events
See the latest BAGIM Meetups HERE ...

See JOB OPPORTUNITIES on the BAGIM Message Board ...
BAGIM is sponsored by Scilligence, Silicon Therapeutics, Acellera, Cyrus Biotechnology, DNASTAR, OpenEye Scientific Software, Schrodinger, Chemical Computing Group, ARIAD Pharmaceuticals, Vertex Pharmaceuticals, the Cambridge Crystallographic Data Centre, Optibrium, Dassault Systemes, Dotmatics, LabAnswer, and ChemAxon.

Alisha Caliman (Organizer) posted a new announcement in Boston Area Group for Informatics and Modeling (BAGIM)

Panel Discussion on Navigating your Career Path - Blueprint Medicines

I hope you all had a great summer. The BAGIM team has worked hard all summer setting up the next series of talks and networking events for you. These events will soon be posted.
In the mean time, I would like to make you all aware of a panel discussion on Sept 26 hosted by Blueprint Medicines as a part of their Catalyst Series. This is a networking event  featuring women in chemistry, and will be at Blueprint Medicines on September 26th, 2019, 4-8pm.
They will kick off Catalyst II with a refreshing session of lighting talks where extremely bright, highly energetic graduate students and postdocs will give 5 min talks one after another. Next, a panel discussion with leading women in biotech/pharma on navigating the career path as a woman in chemistry will follow. The confirmed speakers are Kathy Lee (Pfizer), Janeta Popovici-Muller (Decibel Therapeutics), Rosana Kapeller (GV), Nancy Ryan Gray (Gordon Research Conferences,) and the panel will be moderated by Kate Haviland (Blueprint Medicines). There will also have plenty of time to connect with each other while enjoying a glass of wine.

for more information ...
Click here to register ...
Past Events